Office Management Working Student

Discovery Life Sciences and Mindpeak partner to bring AI precision to cancer biomarker testing in global clinical trials. Mar 24, 2026, 08:00 ET New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /CNW/ - Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challenges in clinical trial development, contributing to variability in patient stratification and eroding confidence in critical go/no-go decisions. Discovery Life Sciences (Discovery), a provider of biospecimens and biomarker specialty lab services, and Mindpeak, a leading company in AI-powered digital pathology, today announced a partnership designed to address that problem directly, integrating AI-enabled digital image analysis into pathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials. The collaboration aims to support biopharma R&D and clinical research by improving biomarker quantification and inter-reader concordance, helping to reduce variability, de-risk biomarker-driven trials and strengthen confidence in critical development decisions. The partnership couples Mindpeak's AI platform with Discovery's tissue biomarker services to analyze IHC and mIF slides. Mindpeak's technology acts as a safeguarding tool for biopharma, reducing risks in biomarker development by improving consistency in interpretation across pathologists. It includes AI-enabled pathology workflows, pathologist training via Mindpeak's peakAcademy, and AI-guided microdissection algorithms to isolate specific tissue regions with high accuracy. Discovery brings significant clinical infrastructure to the alliance. Its Biomarker Academy, a peer-to-peer pathologist training program established in 2008, has trained more than 6,000 pathologists in biomarker interpretation and scoring over the past 15 years. Discovery has supported more than 2,000 clinical trial programs, with 350 currently active, and has completed over 35 IVDR-compliant studies across 16 EU countries involving 25 biomarkers in the past four years. This partnership extends Discovery's AI advancements, building on existing H&E-focused AI solutions for biospecimen analysis, including automated quality control, tumor quantification, and detailed tumor microenvironment characterization across various therapeutic areas. "As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis," said Greg Herrema, CEO of Discovery Life Sciences. "Combining these AI capabilities with our clinical trials expertise will help assist in advancing the development of biomarker-focused therapies." The Mindpeak and Discovery alliance aims to streamline trial processes and enhance data reproducibility in regulated settings, supporting more confident decisions in patient stratification and therapeutic development. "This collaboration with Discovery Life Sciences provides access to our AI platform, training and microdissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," said Felix Faber, Founder and CEO of Mindpeak. Additional details on the partnership and use cases will be presented at the AACR Annual Meeting 2026. Attendees can join a flash talk at the Discovery Life Sciences exhibit from April 17-22 at the San Diego Convention Center in San Diego, California. Contact [email protected] for more information. About Discovery Life Sciences Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through our comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, we deliver critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives. Visit www.dls.com and follow us on LinkedIn for more information. About Mindpeak Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications. Discovery Life Sciences Media Todd Poley Chief Marketing Officer +1 256 505 1578 [email protected] Mindpeak Media Tanya von Ahlefeldt MD Health - on behalf of Mindpeak +44 (0)7590 754906 [email protected] SOURCE Discovery Life Sciences

Mindpeak, an AI-driven pathology startup, raised $15.3 million in a Series A round led by ZEISS Ventures and InnoVentureFund in 2024. The funding will accelerate development and deployment of the company's AI diagnostic tools for cancer pathology. Founded in 2018, Mindpeak's algorithms have supported over 30,000 patient diagnoses across US and European healthcare markets. The technology uses automated histological analyses to help pathologists make faster, more precise clinical decisions. CEO Felix Faber stated the capital would expedite product rollouts and expand capabilities. The company has established strategic partnerships with major players including Roche. Mindpeak operates in the rapidly growing digital pathology market, driven by technological innovation and increasing demand for advanced diagnostic services in an ageing population.

PathGroup chooses mindpeak to power its digital pathology transformation. PathGroup and Mindpeak: Collaboration accelerates AI adoption across one of the world's largest fully digital laboratory networks HAMBURG, GERMANY, November 11, 2025 /EINPresswire.com/ - Mindpeak, a global pioneer in AI-powered pathology solutions, today announced a strategic collaboration with PathGroup, a premier provider of anatomic, clinical, molecular and digital pathology services. The collaboration marks a significant milestone in the evolution of AI-driven pathology, uniting Mindpeak's proprietary image analysis technology with PathGroup's extensive, pathologist-led diagnostic network. By combining deep pathology expertise with advanced AI, the collaboration will accelerate the adoption of scalable, interoperable solutions across large diagnostic networks and research environments. PathGroup operates one of the largest fully digitised pathology networks in the world and is widely recognised as a pioneer in diagnostic innovation. With its advanced digital infrastructure, subspecialist pathologists and streamlined workflows, PathGroup represents an ideal environment to scale AI adoption and set new standards for diagnostic excellence. "As our practice has continued to adopt and integrate industry leading-technology solutions, it makes perfect sense that we would be partnering with Mindpeak for at-scale use of best-in-class AI algorithms, to the benefit of the patients we serve," said Derek C. Welch, MD, FCAP, President and Chief Medical Officer at PathGroup. "This is especially true for cancer patients. The team at Mindpeak share the notion that computational pathology and artificial intelligence are here now and have the power to enhance patient lives today. The tools Mindpeak brings to the market certainly support this notion and we are excited to be partners at this pivotal time in global pathology service transformation. It is truly exciting." Felix Faber, Founder and CEO of Mindpeak, commented: "We're delighted to partner with PathGroup - a leader whose values and expertise align closely with our mission to make AI an everyday tool in pathology. Together, we're pioneering innovation in digital diagnostics and helping laboratories and clinicians deliver faster, more consistent and equitable insights for patients. This collaboration represents a major step forward in bringing the benefits of AI into routine diagnostic practice." Erik Piorkowski, Mindpeak's Head of Diagnostic Sales, Americas, added: "The collaboration will begin with the deployment of Mindpeak's Breast Suite and PD-L1 AI solutions, supporting macro-dissection workflows and expanding decision-support capabilities across PathGroup's large-scale operations. This marks an exciting step forward in accelerating the integration of AI-powered precision into diagnostic practice." By leveraging PathGroup's vast diagnostic network and expert pathologist community, the rollout will generate robust clinical evidence and drive real-world adoption across multiple laboratory settings. This will help lay the foundation for broader digital transformation across pathology services. As Imad B. Nijim, Senior Vice President and Chief Information Officer, PathGroup, noted: "At PathGroup, we are committed to a digital transformation that harnesses cutting-edge technology to advance diagnostic precision and patient care. Our collaboration with Mindpeak represents a significant step toward integrating AI into our pathology workflows. I am excited about this partnership as it reflects a shared vision for a future where artificial intelligence is seamlessly embedded in healthcare, transforming how we detect, diagnose, understand and treat diseases." Together, Mindpeak and PathGroup are laying the foundation for the next wave of AI-powered decision support in pathology. PathGroup's more than 240 sub-specialty expert pathologists will utilise Mindpeak's solutions as they collaborate seamlessly to drive unsurpassed diagnostic precision for patient and physicians. This rollout will also generate robust clinical evidence to accelerate adoption across diverse laboratory settings. Key benefits of the collaboration include: | Accelerated AI adoption - enabling faster implementation of digital pathology in high-throughput diagnostic environments. | Enhanced diagnostic consistency - reducing inter-observer variability and supporting confident clinical decisions. | Scalable insights - integrating AI seamlessly across multi-site networks and research programmes. | Future-ready innovation - advancing biomarker discovery, predictive analytics and personalised medicine. This collaboration reflects Mindpeak's continued growth in the US, following the opening of its office in Boston, Massachusetts earlier this year and reinforces its ambition to shape the future of pathology through AI - from translational research to clinical diagnostics - around the world. About mindpeak. Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications. About PathGroup. Founded in 1965, PathGroup is a premier provider of anatomic, clinical, molecular and digital pathology services in the United States. As a physician-led practice, PathGroup works seamlessly with customers to provide superior diagnostic services - a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry-standard technology, including an industry-leading deployment of digital pathology across its organization, to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. PathGroup is more than a laboratory - it is a trusted partner in health, driven by a mission to improve lives through diagnostic excellence and innovation. Media contacts. Tanya von Ahlefeldt MD Health - on behalf of Mindpeak [email protected] +44 (0)7590 754906 Brent Sower Vice President of Commercial Strategy - PathGroup [email protected] 615-234-3908